Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH

Kim, W; Li, MZ; Liao, XM; Özmen, S; Yildiz, E; Saraçoglu, M; Baba, C; Celikezen, FC; Atalay, SA; Akkus, AT; Türkez, Hasan; Alper, F; Jin, H; Yang, H; Iqbal, S; Sebhaoui, J; Ashraf, S; Belmen, B; Boren, J; Uhlen, M; Zhang, C; Mardinoglu, A

doi:10.3389/fphar.2026.1823203

Makale Tam Makale Uluslararası 2026

Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH

W Kim, MZ Li, XM Liao, S Özmen, E Yildiz, M Saraçoglu, C Baba, FC Celikezen, SA Atalay, AT Akkus, Hasan Türkez, F Alper, H Jin, H Yang, S Iqbal, J Sebhaoui, S Ashraf, B Belmen, J Boren, M Uhlen, C Zhang, A Mardinoglu

FRONTIERS IN PHARMACOLOGY Cilt 17 · 01.07.2026

DOI ile aç

Anahtar kelimeler

MASLD Hepatic steatosis DNL <italic>de novo</italic> lipogenesis JNK (c-Jun N-terminal kinase) new drug

Atıf için künye

Kim, W., Li, M., Liao, X., Özmen, S., Yildiz, E., Saraçoglu, M., Baba, C., Celikezen, F., Atalay, S., Akkus, A., Türkez, H., Alper, F., Jin, H., Yang, H., Iqbal, S., Sebhaoui, J., Ashraf, S., Belmen, B., Boren, J., … Mardinoglu, A. (2026). Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH. FRONTIERS IN PHARMACOLOGY, 17. https://doi.org/10.3389/fphar.2026.1823203

BibTeX

@article{kim2026-244958,
  author = {Kim, W and Li, MZ and Liao, XM and Özmen, S and Yildiz, E and Saraçoglu, M and Baba, C and Celikezen, FC and Atalay, SA and Akkus, AT and Türkez, Hasan and Alper, F and Jin, H and Yang, H and Iqbal, S and Sebhaoui, J and Ashraf, S and Belmen, B and Boren, J and Uhlen, M and Zhang, C and Mardinoglu, A},
  title = {Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH},
  journal = {FRONTIERS IN PHARMACOLOGY},
  year = {2026},
  volume = {17},
  issn = {1663-9812},
  doi = {10.3389/fphar.2026.1823203},
  url = {https://akademik.atauni.edu.tr/yayinlar/244958-targeting-pklr-and-lipogenic-enzymes-through-jnk-inhibition-to-develop-a}
}